elearn.nsh.org

PD-L1 Testing and Immunotherapy

Recorded On: 05/24/2017

  • Register
    • Non-member - $15
    • Core Member - $10
    • Student Member - $10
    • Enhanced Member - Free!

The presentation provides an overview of: the relevance of PD-L1 as a cancer biomarker,the difference between the FDA classification of Complementary vs Companion Diagnostics, Targeted Therapy vs. Immunotherapy, Current FDA approved PD-L1 IHC assays and indications for use & scoring, Current FDA approved anti-PD1/anti-PD-L1 immunotherapies, Immunotherapy Clinical trial data. 

CEUs: This histology course is worth 1 continuing education credit. Course is available for 365 days from date of purchase.

Key:

Complete
Failed
Available
Locked
PD-L1 Testing and Immunotherapy
Open to view video.
Open to view video. The presentation provides an overview of: the relevance of PD-L1 as a cancer biomarker,the difference between the FDA classification of Complementary vs Companion Diagnostics, Targeted Therapy vs. Immunotherapy, Current FDA approved PD-L1 IHC assays and indications for use & scoring, Current FDA approved anti-PD1/anti-PD-L1 immunotherapies, Immunotherapy Clinical trial data
On Demand Webinar Survey
2 Questions
2 Questions Please complete the survey to receive your CEU certificate.
Certificate
1.00 CEUs credit  |  Certificate available
1.00 CEUs credit  |  Certificate available